Literature DB >> 15026082

The proliferative effects of 5-androstene-3 beta,17 beta-diol and 5 alpha-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines.

S R Aspinall1, S Stamp, A Davison, B K Shenton, T W J Lennard.   

Abstract

Epidemiological studies suggest that precursor steroids are implicated in the aetiology of breast cancer. However, our understanding of the role of precursor steroids in breast cancer is complicated by fact that there are many precursor steroids, which are metabolically inter-related and have divergent proliferative activities on the growth of breast cancer cell lines. In this study the proliferative affects of 5 alpha-dihydrotestosterone and 5-androstene-3 beta,17 beta-diol, which may be considered true metabolites acting at a tissue level, on MCF7, T47D and MDAMB231 breast cancer cell lines have been examined by a flow cytometric technique. DNA cell cycle analysis demonstrates that 5-androstene-3 beta,17 beta-diol stimulates the proliferation of hormone-dependent cell lines at physiological levels by an oestrogen receptor mediated mechanism whereas 5 alpha-dihydrotestosterone does not affect the proliferation of MCF7 and T47D cell lines at physiological levels over short (48 h) incubations. Both 5 alpha-dihydrotestosterone and 5-androstene-3 beta,17 beta-diol stimulate proliferation of hormone-dependent cell lines at pharmacological levels via and interaction with the oestrogen receptor. In long (6-9 days) incubations both 5 alpha-dihydrotestosterone and 5-androstene-3 beta,17 beta-diol inhibit the 17 beta-oestradiol induced proliferation of MCF7 and T47D cell lines, however, 5 alpha-dihydrotestosterone inhibits while 5-androstene-3 beta,17 beta-diol stimulates basal proliferation. These cell line studies suggest a model for the role of precursor steroids in pre- and postmenopausal breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026082     DOI: 10.1016/j.jsbmb.2003.10.011

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

1.  The effect of physiological concentrations of sex hormones, insulin, and glucagon on growth of breast and prostate cells supplemented with unmodified human serum.

Authors:  Amin Esfahani; Cyril W C Kendall; Balachandran Bashyam; Michael C Archer; David J A Jenkins
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-10-07       Impact factor: 2.416

2.  17beta-hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production.

Authors:  Juliette A Aka; Mausumi Mazumdar; Chang-Qing Chen; Donald Poirier; Sheng-Xiang Lin
Journal:  Mol Endocrinol       Date:  2010-02-19

3.  Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7.

Authors:  Juliette Adjo Aka; Juliette Adjo Aka; Sheng-Xiang Lin
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

4.  Effects of 3-beta-diol, an androgen metabolite with intrinsic estrogen-like effects, in modulating the aquaporin-9 expression in the rat efferent ductules.

Authors:  Patrícia Picciarelli-Lima; André G Oliveira; Adelina M Reis; Evanguedes Kalapothakis; Germán A B Mahecha; Rex A Hess; Cleida A Oliveira
Journal:  Reprod Biol Endocrinol       Date:  2006-10-06       Impact factor: 5.211

5.  IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.

Authors:  Carlo Palmieri; Richard Szydlo; Marie Miller; Laura Barker; Neva H Patel; Hironobu Sasano; Tara Barwick; Henry Tam; Dimitri Hadjiminas; Jasmin Lee; Abeer Shaaban; Hanna Nicholas; R Charles Coombes; Laura M Kenny
Journal:  Breast Cancer Res Treat       Date:  2017-08-09       Impact factor: 4.872

Review 6.  The Regulation of Steroid Action by Sulfation and Desulfation.

Authors:  Jonathan W Mueller; Lorna C Gilligan; Jan Idkowiak; Wiebke Arlt; Paul A Foster
Journal:  Endocr Rev       Date:  2015-07-27       Impact factor: 19.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.